Allegro Diagnostics Announces BronchoGen Genomic Test for Improved Diagnosis of Lung Cancer Successfully Achieves Clinical Validation
3/12/2013 9:25:54 AM
MAYNARD, Mass.--(BUSINESS WIRE)--Allegro Diagnostics today announced that the AEGIS I clinical trial has met its primary endpoint, demonstrating that the BronchoGen™ genomic test improves the accuracy of lung cancer diagnosis when used in combination with bronchoscopy. BronchoGen is Allegro Diagnostics’ lead genomic test, and it is built upon the Company’s molecular testing platform that utilizes gene expression of cytologically normal epithelial cells in the respiratory tract to aid in the diagnosis of lung cancer. Endpoints in the clinical trial include the sensitivity, specificity and negative predictive value of BronchoGen for identifying patients with malignancy. Allegro plans to submit the complete results from the clinical trial for publication in a peer-reviewed journal.
comments powered by